From: Role of bile acids in the prediction of hepatocellular carcinoma in HCV-induced liver cirrhosis
NHC | NCLD | CLD | HCC | |
---|---|---|---|---|
Age, mean (range) | 45 (34–73) | 46 (36–69)NS | 46 (37–70)NS | 46 (37–69)NS |
BMI (kg/m2) | 23.5 ± 0.4 | 23.6 ± 0.3NS | 22.9 ± 0.3NS | 23.4 ± 0.3NS |
Sex | ||||
Male | 25 (50%) | 19 (38%) | 29 (58%) | 15 (30%) |
Female | 25 (50%) | 31 (62%) | 21 (42%) | 35 (70%) |
AFP ng/ml, median (IQR) | 1.7 (0.8) | 2.3 (1.2) NS | 3.7 (4.4)* | 68.4 (877)* |
Child-Pugh class, A/B/C | 38 (76%)/8 (16%)/4 (8%) | 18 (36%)/17 (34%)/15 (30%) | ||
HFL, single/multiple | 19 (38%)/31 (62%) | |||
Metastasis, No/Yes | 46 (92%)/4 (8%) | |||
Lymph node, No/yes | 43 (86%)/7 (14%) | |||
PV invasion, No/yes | 50 (100%)/0 (0%) | |||
Barcelona, HCC stage A/B/C | 36 (72%)/10 (20%)/4 (8%) | |||
AST (IU/L) | 20.7 ± 6.5 | 39.8 ± 34.4* | 56.6 ± 35* | 55.4 ± 29.2* |
ALT (IU/L) | 20.2 ± 8.6 | 41.3 ± 36.7* | 41.9 ± 44.2* | 31.9 ± 18.5* |
GGT (IU/ml) | 23 ± 13 | 35 ± 22* | 71 ± 53* | 73 ± 61* |
ALP (IU/ml) | 60.3 ± 22.6 | 74.5 ± 47 NS | 113.5 ± 57* | 117.2 ± 49.2* |
TBil (mg/dl) | 0.5 ± 0.2 | 0.6 ± 0.3* | 1.5 ± 1.6* | 1.5 ± 1.2* |
DBil (mg/dl) | 0.2 ± 0.1 | 0.2 ± 0.1 NS | 1.2 ± 1.7* | 0.8 ± 0.7* |
ALB (g/dl) | 4 ± 0.2 | 4.7 ± 0.3 | 3.5 ± 0.8* | 3.3 ± 0.7* |
TP (mg/dl) | 7 ± 0.9 | 8 ± 0.4 NS | 8 ± 0.7 NS | 7 ± 0.7* |
Hb ( g/l ) | 134 ± 12 | 131 ± 15 NS | 119.8 ± 20* | 120 ± 20* |
Platelets x (109/l) | 290.9 ± 72.2 | 259 ± 91 NS | 132.3 ± 63.8* | 128.7 ± 63.1* |
WBCs x (109/l) | 7.3 ± 1.4 | 6.9 ± 1.5 NS | 5.4 ± 2.3* | 5 ± 1.9* |